First data for Lilly’s RNA treatment for heart disease point to long-term durability in tiny group of patients

Eli Lilly’s investigational RNA silencing drug lowered levels of lipoprotein(a) in an early-stage study.

Elevated levels of Lp(a) have been associated with a higher risk of heart disease, heart attack and stroke.

In 48 adult participants with elevated Lp(a) levels who did not have heart disease, researchers tested six different…
Click here to view original post